Diabetic associated gastroparesis (GP), manifested by intractable vomiting, nausea, and abdominal pain, and is a common presentation to the emergency department (ED). Conventional treatment is focused on symptomatic management and has historically focused on the use of prokinetic agents, and antiemetics, with or without an opioid agent for intractable pain; however, no algorithm currently exists. Given its novel mechanism of action as a dopamine-2 (D2) receptor antagonist, haloperidol may be an effective alternative agent, due to its analgesic and antiemetic properties. This study seeks to determine if using haloperidol in lieu of conventional agents reduces overall ED length of stay and reduces hospital admissions.
